Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) and units Chengdu Shandi Pharmaceutical and Tianjin Hengrui Pharmaceutical obtained the approval of China's drug administrator to start clinical trials for HRS4357 injection and HRS5041 tablet.
The approvals would allow for the study to evaluate the safety, tolerability and preliminary efficacy of HRS4357 combined with HRS5041 for the treatment of prostate cancer, according to a filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments